UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a research report released on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 price objective on the stock.

Several other analysts have also recently weighed in on URGN. The Goldman Sachs Group reduced their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $55.00 target price on shares of UroGen Pharma in a report on Monday. Finally, Scotiabank began coverage on UroGen Pharma in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $32.86.

UroGen Pharma Stock Up 0.9 %

UroGen Pharma stock traded up $0.10 during mid-day trading on Monday, reaching $11.51. 484,891 shares of the company's stock were exchanged, compared to its average volume of 533,225. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma has a twelve month low of $8.94 and a twelve month high of $20.70. The company has a market cap of $530.54 million, a P/E ratio of -3.65 and a beta of 0.80. The company has a fifty day moving average of $10.50 and a 200-day moving average of $11.07.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Sell-side analysts expect that UroGen Pharma will post -3.12 EPS for the current year.

Institutional Trading of UroGen Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Toronto Dominion Bank purchased a new stake in UroGen Pharma in the fourth quarter valued at approximately $18,628,000. Acorn Capital Advisors LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $16,149,000. Nantahala Capital Management LLC purchased a new stake in UroGen Pharma in the 4th quarter valued at $14,608,000. Vestal Point Capital LP boosted its stake in UroGen Pharma by 307.5% during the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company's stock worth $17,360,000 after purchasing an additional 1,230,000 shares during the period. Finally, Rosalind Advisors Inc. purchased a new position in UroGen Pharma during the 4th quarter worth $9,266,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.